Rockeby European patent granted for CanDia5
Rockeby biomed Ltd announced that it has been granted an European Patent by the European Patent Office, with relation to CanDia5 candida assay patent.
The Patent (European Patent No. 1 381 864) relates to a method and a means of diagnosing Candida infection. In particular the present invention relates to a method of diagnosing Candida infection which is both sensitive and rapid. This further extends Rockeby’s patent coverage of its Candida diagnosis technology to the United Kingdom from countries (Australia, Japan and USA) that had previously granted patents.
Rockeby currently markets and distributes CanDia5® in Australia, New Zealand, Italy, Singapore and United Arab Emirates.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

SUANFARMA announces a collaboration with Reyoung Pharmaceutical - The main objective of the collaboration is to introduce generic pharmaceutical ingredients to the market for the treatment of infectious diseases
Bayer: YAZ approved in Japan for the treatment of dysmenorrhea

Nanoparticles used to transport anti-cancer agent to cells
